ImmuCell Corp (ICCC) stock

ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3021% above fair value

$10.75+0.53 (+5.19%)

Close on Nov 13, 2026Market cap $97.63MP/E 53.8Yield –

Earnings

ImmuCell's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Mar 3, 2027

Q4 FY2026 · estimated, after the close

Revenue, Q3 FY2026

$8.00M

+45.5% on a year earlier

EPS, Q3 FY2026

–

-$0.02 a year earlier

Latest guidance

None

No outlook given in releases

Quarterly results

Revenue and earnings per share from each of ImmuCell's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Source
Q4 FY2026ended Dec 31, 2026	Mar 3, 2027Expected	–	–	–	–
Q3 FY2026ended Sep 30, 2026	Oct 13, 2026before the open	$8.00M	+45.5%	–	Release
Q2 FY2026ended Jun 30, 2026	Aug 13, 2026after the close	$7.20M	+12.5%	$0.20	Release
Q1 FY2026ended Mar 31, 2026	May 14, 2026after the close	$10.40M	–	$0.21	Release
Q4 FY2025ended Dec 31, 2025	Mar 4, 2026after the close	$7.63M	-2.2%	-$0.31	Release
Q3 FY2025ended Sep 30, 2025	Nov 13, 2025after the close	$5.50M	–	-$0.02	Release
Q2 FY2025ended Jun 30, 2025	Jul 9, 2025before the open	$6.40M	+17.0%	–	Release
Q1 FY2025ended Mar 31, 2025	Apr 8, 2025after the close	–	–	–	Release
Q4 FY2024ended Dec 31, 2024	Feb 25, 2025after the close	$7.80M	+52.9%	$0.06	Release
Q3 FY2024ended Sep 30, 2024	Oct 8, 2024after the close	–	–	–	Release
Q2 FY2024ended Jun 30, 2024	Jul 9, 2024after the close	$5.47M	+55.0%	–	Release
Q1 FY2024ended Mar 31, 2024	Apr 9, 2024after the close	$7.30M	+111.6%	–	Release
Q4 FY2023ended Dec 31, 2023	Feb 27, 2024after the close	$5.10M	–	-$0.15	Release
Q3 FY2023ended Sep 30, 2023	Oct 5, 2023after the close	$5.40M	–	–	Release
Q2 FY2023ended Jun 30, 2023	Jul 11, 2023after the close	$3.53M	-9.5%	–	Release
Q1 FY2023ended Mar 31, 2023	Apr 5, 2023after the close	$3.45M	-42.5%	–	Release
Q4 FY2022ended Dec 31, 2022	Feb 21, 2023after the close	–	–	–	Release
Q3 FY2022ended Sep 30, 2022	Nov 10, 2022after the close	–	–	–	Release
Q2 FY2022ended Jun 30, 2022	Jul 7, 2022after the close	$3.90M	–	–	Release
Q1 FY2022ended Mar 31, 2022	Apr 11, 2022during market hours	$6.00M	–	–	Release
Q4 FY2021ended Dec 31, 2021	Feb 22, 2022after the close	$5.40M	–	–	Release
Q3 FY2021ended Sep 30, 2021	Oct 6, 2021during market hours	$5.20M	–	–	Release
Q2 FY2021ended Jun 30, 2021	Jul 7, 2021during market hours	–	–	–	Filing
Q1 FY2021ended Mar 31, 2021	Apr 7, 2021during market hours	–	–	–	Filing
Q4 FY2020ended Dec 31, 2020	Feb 23, 2021during market hours	–	–	–	Filing
Q3 FY2020ended Sep 30, 2020	Oct 6, 2020during market hours	–	–	–	Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

ImmuCell has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When ImmuCell puts a forecast in an earnings release, it is listed here with the exact sentence.